세계의 암 치료 시장 규모는 2020년 1,552억 3,000만 달러로 평가되었고, 2030년까지 2,663억 1,000만 달러에 이를 전망이며, 2024년부터 2030년까지 예측 기간에 CAGR 9.12%의 성장이 전망됩니다. 시장은 암 치료 수요 증가에 기여하고 있는 다양한 암의 유행 및 유방암 등의 특정 암종에서, 연령이 발병에 중요한 역할을 하기 때문에 노년 인구 증가 등의 요인 존재로 긍정적인 시장 성장을 보여줍니다. 또한, 보다 현저한 치료 효과를 가져오는 정밀의료의 진보에 의해 표적요법의 개발에 주목을 받고 있는 것도, 신제품이 암 치료의 규제 당국의 승인을 얻고 있기 때문에 암 치료 시장을 더 견인하고 있습니다.
암 치료 시장 역학
암 치료 시장의 주요 촉진요인 중 하나는 암 이환율의 급증입니다. International Agency for Research on Cancer가 실시한 GLOBOCAN 조사에 따르면 2020년에 세계에서 새롭게 1,930만명의 암 환자가 발생하였고, 약 1,000만명이 사망한 것으로 추정되고 있습니다. 또한 상기 자료에 따르면 2020년 암 관련 사망의 주요 원인은 폐암이 180만명으로 가장 많았으며, 이어 대장암(9.4%), 간암(8.3%), 위암(7.7%), 여성 유방암(6.9%)입니다. 암은 신체를 쇠약시키는 질환이기 때문에 암세포를 치료하기 위해서는 대규모 치료가 필요합니다. 수술, 화학요법, 방사선요법 등 다양한 치료법이 암 치료에 채용되고 있는 것은 암 치료에 있어서 치유 효과뿐만 아니라 완화 효과도 얻을 수 있다는 이점이 있기 때문입니다. 이와 같이 다양한 유형의 암 치료에 대한 요구 증가는 다양한 유형의 치료에 반응할 가능성이 있는 암의 이환율 증가에 의한 것으로 예상됩니다. 따라서 앞서 언급한 요인은 모두 암 치료에 대한 수요 증가에 기여하며, 결과적으로 세계 암 치료 시장의 성장을 뒷받침할 것으로 예측됩니다.
암 치료 시장의 성장을 뒷받침하는 또 다른 특징은 암 치료에서 정밀의료의 인기가 증가하는 것입니다. 예를 들어, 정밀의료는 진단에서 투여 가능한 치료법의 고안까지 암 치료의 다양한 단계에서 의사를 지원합니다. 종양의 유형화는 정밀의료의 주요 분야 중 하나이며, 종양의 발생 및 치료 저항성에 관여하는 유전자의 유형를 확인함으로써 예후를 개선하는 표적 치료의 개발에 길을 열어줍니다.
게다가, RNA 시퀀싱 및 차세대 시퀀싱과 같은 신기술의 개발은 예지 및 예후 분자 변화의 검출을 향상시키고 보다 개별화된 접근법을 추진하는데 매우 중요합니다. 예를 들어 미국에 본사를 둔 National Cancer Institute(NCI)는 암 치료에 관한 정밀의료 프로그램에 많은 투자를 하고 있습니다. 현재 진행 중인 NCI 프로그램에는 NCI Translational and Therapeutic Studies, NCI Immunology and Immunotherapy Research, NCI Genomics and Cancer Biology Research 등이 있습니다. 이것은 향후 수년간 시장에 등장할 수 있는 다수의 치료법을 나타내고 있으며, 예측기간 암 치료 시장의 성장을 더욱 뒷받침할 것입니다.
그러나 골량의 감소 등 다양한 암 치료에 수반되는 잠재적인 부작용이나 특히 저중소득국에서의 암 치료 비용이 암 치료 시장 성장에 있어서의 과제가 될 가능성이 있습니다.
암 치료 시장은 COVID-19의 확대를 억제하기 위한 대책의 실시에 의해 부정적인 영향을 받았습니다. COVID-19 전염병으로 인한 응급 상황에 대응하기 위해, 다른 모든 의료 전문 분야에서는 환자 수가 감소했습니다. 예를 들어, Cancer Research UK에 따르면 영국만으로도 봉쇄 초기에 긴급 폐암의 소개는 최대 75% 감소했습니다. 이것은 사례의 감소와 상관없이 긴급히 필요한 진단을 추구하였고, 진단을 받는 사람이 줄었다는 것입니다. 불행히도, 이러한 동향은 세계 각국에서 두드러졌습니다. 그럼에도 불구하고, 암 의료를 변혁하는 전략의 고안에 의해 암 치료 시장은 회복 기조에 있으며, 그에 의해 2024년부터 2030년까지 예측 기간 암 치료 시장의 미래에 전망이 나타나고 있습니다.
본 보고서에서는 세계의 암 치료 시장에 대해 조사 분석하여 시장 규모 및 예측, 촉진요인 및 과제, 기업 및 제품 프로파일 등의 정보를 제공합니다.
Cancer Therapy Market By Therapy Type (Chemotherapy, Radiation Therapy, Hormonal Therapy, Targeted Therapy, And Others), By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Blood Cancers, And Others), By End User (Hospitals, Specialty Clinics, And Others), and by geography is expected to advance at a respectable CAGR forecast till 2030 owing to rising prevalence of various cancers such as lung and breast cancers and growing demand for targeted therapies for cancer treatment
Global cancer therapy market was valued at USD 155.23 billion in 2020, growing at a CAGR of 9.12% during the forecast period from 2024 to 2030, in order to reach USD 266.31 billion by 2030. The cancer therapy market is witnessing a positive market growth owing to the factors such as rising prevalence of various cancers which are contributing in the growing demand for cancer treatment, and presence of factors like increasing aging population wherein age plays a key role in cancer development in certain cancer types namely breast cancer. Moreover, the growing focus on developing targeted therapies due to advancements in precision medicine to provide a more pronounced therapeutic effect is further driving the cancer therapy market as new products are gaining regulatory approvals for cancer treatment.
Cancer Therapy Market Dynamics:
One of the key aspects driving the cancer therapy market can be attributed to the surge in cancer incidence. The GLOBOCAN study conducted by the International Agency for Research on Cancer mentioned that in 2020, an estimated number of 19.3 million new cancer cases and approximately 10.0 million cancer deaths were reported globally. The source mentioned above also stated that in 2020, lung cancer was the main cause accounting for the highest number (1.8 million) of cancer-related deaths followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%) cancers. Cancer, being a debilitating disease, requires extensive treatment in order to treat cancerous cells. Various therapies such as surgery, chemotherapy, and radiation therapy are employed in cancer treatment due to the benefits associated with them in terms of providing curative as well as palliative effect in cancer treatment. Thus, the growing need for cancer therapy of various types can be attributed to the increasing cancer incidence which may respond to different therapy types. Therefore, all the aforementioned factors are projected to contribute growing demand for cancer therapy, ultimately boosting the growth of the global cancer therapy market.
Another aspect that is aiding in the growth of the cancer therapy market is the growing popularity of precision medicine in cancer treatment. For instance, precision medicine enables doctors in various stages of cancer treatment right from diagnosis to devising the type of therapy that can be administered. Tumor typing is one the key areas in precision medicine which helps in identifying the type of gene/s that play a role in tumor development as well as therapy resistance thereby paving the way for the development of targeted therapy to achieve better prognostic outcomes.
Furthermore, the development of newer technologies such as RNA sequencing and next generation sequencing have been monumental in driving a more personalized approach with improvements in detecting predictive and prognostic molecular alterations. For instance, the National Cancer Institute (NCI) based in the United States has heavily invested in precision medicine programs pertaining to cancer treatment. A few of the ongoing NCI programs include NCI Translational and Therapeutic Studies, NCI Immunology and Immunotherapy Research, NCI Genomics and Cancer Biology Research among others. This indicates the plethora of potential therapies that may reach the market in coming years, further boosting the growth of cancer therapy market during the forecast period.
However, potential side-effects associated with different cancer therapies such as loss of bone mass and cost of cancer therapies especially in low- and middle-income countries may prove to be challenging factors for cancer therapy market growth.
The cancer therapy market was negatively impacted by the implementation of measures to curb the spread of the COVID-19 infection. In order to cater to the exigency created by the COVID-19 pandemic, all other medical specialties witnessed a reduction in patient load. For instance, according to Cancer Research UK, in the UK alone, for example, urgent lung cancer referrals fell by up to 75% during the first lockdown. This did not correlate to the decrease in cases, but that fewer people sought and obtained the diagnosis they urgently need. Unfortunately, these trends were prominent across countries around the globe. Nevertheless, the market for cancer therapy is on a period of recovery owing to devising of strategies to transform cancer care thereby presenting a future outlook for cancer therapy market during the forecast period from 2024-2030.
Cancer Therapy Market Segment Analysis:
Cancer Therapy Market by Therapy Type (Surgery, Chemotherapy, Radiation Therapy, Hormonal Therapy, Targeted Therapy, and Others), by Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Blood Cancers, and Others), by End User (Hospitals, Specialty Clinics, and Others), and by Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the therapy type segment of the cancer therapy market, the chemotherapy category is estimated to register significant share in market revenue during the forecast period (2024-2030). This can be attributed to the advantages associated with chemotherapy. Chemo is considered a systemic treatment because in this, the drug travels throughout the body, and also targets cancer cells that have metastasized to parts of the body far away from the original tumor. This makes chemotherapy different than other localized cancer therapies such as surgery and radiation. Furthermore, often it is conducted in combination with other therapies such as surgery in events to reduce the size of the tumor before removing it surgically.
Therefore, considering the advantages associated with chemotherapy, this therapy category is expected to witness a considerable growth eventually contributing the overall growth of the global cancer therapy market in the forecast period.
North America is expected to dominate the overall Cancer Therapy Market:
Among all the regions, North America is estimated to amass the largest revenue share in the global cancer therapy market. This can be ascribed to the high prevalence of cancers, and a supportive regulatory environment among other factors in the region. Furthermore, high disposable income, sophisticated healthcare infrastructure, and increased awareness regarding new treatments coupled with extensive insurance coverage for these treatments are also expected to aid in the cancer therapy market growth in this region.
One of the key supporting factors for the growth of the North America cancer therapy market is the increasing prevalence of cancers in the United States. As per the figures mentioned by the American Cancer Society, in 2022, it was estimated that 1.9 million new cancer cases would have been diagnosed in the United States. The data provided by the Centers for Disease Control and Prevention (2023), in 2018, 1,708,921 new cases of cancers were reported. For instance, the American Cancer Society estimates that in 2022, approximately 287,850 new cases of invasive breast cancer are expected to be diagnosed in women in the United States. Therefore, the increasing incidence of cancers such as breast cancer in the country is expected to further drive the demand for cancer therapy such as radiation, chemotherapy, targeted therapy, thereby contributing in the growth of the United States cancer therapy market as well the overall growth of the North America cancer therapy market.
Furthermore, due to growing demand for targeted therapies in cancer treatment and extensive research and development in translation research leading to the development of new therapies as well as product approvals for the same. For instance, in September 2022, Health Canada approved LUMAKRAS(TM) (sotorasib) - the first and only targeted treatment for patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer. Similarly, in May 2020, the US Food and Drug Administration granted regulatory approval for the treatment of adult patients with non-small cell lung cancer (NSCLC) that has spread to other parts of the body.
Thus, such product development activities along with other stimulating factors such as the presence of a robust healthcare system and insurance coverage further drive the demand for cancer therapy in the North American region.
Cancer Therapy Market Key Players:
Some of the key market players operating in the cancer therapy market includes GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc, Sanofi, Merck & Co., Inc, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Gilead Sciences, Inc., Janssen Global Services, LLC, Elekta AB, Varian Medical Systems, Inc., Accuray Incorporated, Pyrexar Medical, Eckert & Ziegler, IBA, Panacea Medical Technologies Pvt. Ltd.and others.
Recent Developmental Activities in Cancer Therapy Market:
In October 15, 2022, the US FDA approved atezolizumab (Tecentriq) by Genentech, Inc. for adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II to IIIA non-small cell lung cancer (NSCLC).
In August 2022, Bristol Myers Squibbs received the conditional marketing authorization for Abecma (idecabtagene vicleucel) by the European Commission for the treatment of adult patients with relapsed and refractory multiple myeloma. It is a first-in-class B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy.
In June 2022, the US FDA granted the product approval to Elekta AB's Elekta Harmony radiation therapy system to deliver radiotherapy in the treatment of various cancers such as lung, prostate, and breast cancers.
Key Takeaways from the Cancer Therapy Market Report Study
Target Audience who can be benefited from this Cancer Therapy Market Report Study
Frequently Asked Questions for Cancer Therapy Market:
Cancer therapy encompasses all kinds of cancer treatments such as chemotherapy, radiation therapy, hormonal therapy and targeted therapy among others that aim to kill cancer cells to provide therapeutic effect.
Global cancer therapy market was valued at USD 155.23 billion in 2020, growing at a CAGR of 9.12% during the forecast period from 2024 to 2030 to reach USD 266.31 billion by 2030.
The cancer therapy market is witnessing a positive market growth owing to the factors such as rising prevalence of cancers which are contributing in the growing demand for cancer treatment, and presence of factors such as increasing aging population wherein age plays a key role in cancer development in certain cancer types such as breast cancer. Moreover, the growing focus on developing targeted therapies to provide a more pronounced therapeutic effect is further driving the cancer therapy market as new products are gaining regulatory approvals for cancer treatment.
Some of the key market players operating in the cancer therapy market includes GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc, Sanofi, Merck & Co., Inc, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Gilead Sciences, Inc., Janssen Global Services, LLC,., Elekta AB, Varian Medical Systems, Inc., Accuray Incorporated, Pyrexar Medical, Eckert & Ziegler, IBA, Panacea Medical Technologies Pvt. Ltd.and others.
North America is expected to hold the highest share in the revenue in the Cancer Therapy market during the forecast period. This can be ascribed to the high prevalence of cancers, and a supportive regulatory environment among other factors in the region. Furthermore, high disposable income, sophisticated healthcare infrastructure, and increased awareness regarding new treatments coupled with extensive insurance coverage for these treatments are also expected to aid in the cancer therapy market growth in this region.